Anne Corbett

TL;DR: Pimavanserin was well tolerated with no significant safety concerns or worsening of motor function and may benefit patients with Parkinson's disease psychosis for whom few other treatment options exist.

TL;DR: To address the current inadequate management of pain in dementia, a comprehensive approach is needed, which would include an accurate, validated assessment tool that is sensitive to different types of pain and therapeutic effects, supported by better training and support for care staff across all settings.

TL;DR: This Review summarizes the best-available evidence regarding the aetiology, assessment and treatment of pain in people with dementia and concludes that further validation of assessment tools and large-scale trials of treatment approaches inPeople with dementia are needed to improve clinical guidance for the treatment ofPain in these individuals.

TL;DR: There are a considerable number of pain assessment tools available for use with the elderly cognitive impaired population, however there is limited evidence about their reliability, validity and clinical utility.

TL;DR: A formal consensus evaluation of several compounds for which sufficient evidence is available to encourage further investigation to clarify an optimal dose and consider progression to clinical trials in patients with Alzheimer's disease is presented.